Sermorelin vs FGL
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →FGL
FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | FGL |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Subcutaneous injection or intranasal administration. Research compound with limited human dosing data. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Limited human data available. Animal studies show good tolerability. |
| Best For |